Liver Cirrhosis

Patient randomization of Actimmune phase II trial completed

Published in Hepatitis Weekly, November 25th, 2002

InterMune, Inc. (ITMN) announced that the company has completed patient randomization of its large phase II clinical trial of Actimmune (interferon gamma-1b) injection for the treatment of severe liver fibrosis, or cirrhosis, caused by the hepatitis C virus (HCV).

The objective of the study, called AEGIS (Anti-fibrotic Efficacy Gamma Interferon Study), is to evaluate the safety and antifibrotic activity of Actimmune in HCV patients who have failed standard antiviral therapy.

Henry Hsu, MD, InterMune, said, "Preclinical and preliminary clinical data suggest that interferon gamma may prevent or reverse the development of cirrhosis. Based on these...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry